This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 05
  • /
  • FDA approves Iperia ProMRI HF-T cardiac resynchron...
Drug news

FDA approves Iperia ProMRI HF-T cardiac resynchronization defibrillator for heart failure- Biotronik

Read time: 1 mins
Last updated:5th May 2016
Published:5th May 2016
Source: Pharmawand

The FDA has announced approval of Iperia ProMRI HF-T, a cardiac resynchronization defibrillator, from Biotronik, that provides heart failure patients with access to diagnostic magnetic resonance imaging (MRI) scans. The Iperia HF-T was developed with Biotronik's ProMRI, Home Monitoring, and CLS technology, creating an advanced cardiac resynchronization therapy defibrillator (CRT-D) which ensures patients have access to 1.5T scans without an exclusion zone. Home Monitoring provides automatic daily transmission of data relating to arrhythmic events and heart failure statistics, which have been shown to reduce all-cause mortality by more than 50 percent.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.